( l i n e a r and 4 orthogonal polynomials) was computed of 1.1.1. on time. The r e s i d u a l mean square was much h i g h e r than t h e variance within 6 measurements. The l i n e a r r e g r e s s i o n was s i g n i f i c a n t a t 0.05 l e v e l i n 29 c h i l d r e n . Average (iSD) 1.1.1. growth v e l o c i t y was 0.36t0.14 mm/week, and h e i g h t 1.27i0.54 mm/week (ratio 3.9i2.0'
The 2nd, 3rd, and 4 t h polynomials were s i g n i f i c a n t more o f t e n than expected i f h i g h e r o r d e r e f f e c t s would be absent. When growth vel o c i t i e s were c a l c u l a t e d over t h e f i r s t 6 weeks (v ) and l a s t 6 weeks (v ) , v and v were d i f f e r e n t from z e r o i n 43 and 19 c h i ldren. Mein i AD of t 2 e 31 v v a l u e s were 0.39 and 0.15 mm/week. v a -V~ was s i g n i f i c a n t l y d i f k e r e n t from z e r o i n 5 c h i l d r e n . Mean i S o t h e 31 v -v values were -0.051+0.23 mm/week. I f a one-side 2 1 t e s t i s used, a difference v2-v1 g r e a t e r than 0.37 mm/week i s s l gn i f i c a n t . This corresponds wlth a s t a t u r a l growth response of 7.5 cm/year. In conclusion, observation p e r i o d s of 6 weeks a r e t o o s h o r t f o r a r e l i a b l e comparison of 1. 
U.
of Cadiz (Spain) and Zurich ( S w i t z e r l a n d ) .
The most accepted numerical method f o r t h e assessment of BA i s Tanner-Whitehouse (TW2). However, i t s d i s a d v a ntage i s t h a t i t i s laborious and r e q u i r e s t r a i n e d s t a f f . A method based on computer a n a l y s i s of bone s h a p e a s indicator of maturity h a s been developed. The r e p r e s e n t a t iv e p a t t e r n s of each maturity stage of t h e TW2 a t l a s have 
i t y center of t h e figures and r e p r e s e n t e s t h e v e c t o r i a l r a d i u s from t h e center of g r a v i t y t o t h e point of t h e bone perimeter f o r each d i g i t i z e d point on a coordinate a x i s . The degrees of each vector (0-360Q)
correspond t o a x i s X and t h e length of each vector t o a x i s Y . The unified extremes of t h e v e c t o r s r e s u l t in a r e p r e s e n t a t i v e c u r v e of t h e bone s h a p e . The comparison of a problem c u r v e with t h e catalogue of s t a n d a r d c u r v e s of TW2 a t l a s h a s demonstrated t h a t t h i s method i s e a s i e r t h a n t h e c l a s s i c method .We have treated 15 girls and 5 boys (chron.age 10.1-14.6 years. bone age 11.0-14.9 years) with bromocriptine (2~2.5 mglday) over a period of 1.14 -0.31 years (0.6-1.75). Results (paired Wilcoxon rank test): The differences between the mean adult height prediction before and after bromocriptine were -0.8 ' 3.5 cm according to Bailey-Pinneau (p = 0.433). and t0.2 ' 2.5 cm according to Tanner Mark I (p = 0.586). The mean peak $H values after TRH i .v. were 53.0 ' 50.2 mU/1 before. and 59.0 -50.2 mull during bromocriptine treatment (p = 0.314). The wide range of the GH results most probably reflects physiological variations in this age group. Our results are essentially negative. Moreover. the concept. that bromocriptine reduces GH secretion. seems doubtful: in 6 of our patients we have measured plasma GH after 2.5 mg of bromocriptine and found a significant increase within the first three hours.
Cur results do not support the data from the literature. We conclude. that bromocriptine is ineffective in reducing adult height of tall girls and boys. Supported by Swiss National Science Foundation grant 3.906.083. (IC= integrated concentration; AUC= area under the curve) Fasting serum IGF-1 levels were elevated in 2 girls aged 11 (37 nM/1) and 15 yrs (48 nM/l), and within the normal range in the rest of the sibs (16-43 nM/l), and in the parents (16.5 & 24.2 nM/l), with a si nificant correlation to their basal GH levels (r=.85, p< .02'7.
In conclusion, the pattern of GH secretion in several members of a family with tall stature was reported. In all the sib1 ings an abnormal GH response to TRH and in 3 tested an increased daily output of GH was found.
Recently, BRC has been proposed as a novel agent for the treatment of tall stature in adolescents based on its ability to reduce adult height prediction (HP). Eight boys with a chronological age of 10.3-15.4 yrs (mean 13.3 yrs) were treated for 1 yr with BRC 7.5 mg daily. At the onset of therapy, adult height prediction according to Bayley-Pinneau (HP-BP) was 200.7 to 209.7 cm and according to Tanner Mark I1 (HP-TWII) 199.0-211.5 cm. After 1 yr of therapy, HP with both methods had decreased in every boy, changing by -4.13+ 1.86 (SD) cm (HP-BP) or -3.3522.39 (SD) cm (HP-TWII) , respectively. To substantiate these findings, each patient was pair-matched with a control, an untreated boy with a height above +2SDS and a bone age differing less than 0.5 yr. HP-BP was significantly reduced in patients after 1 yr of BRC compared with their matched controls after 1 yr of follow-up (p less than 0.02). By contrast, differences in HP-TWII were not significant. Because of this discrepancy it is uncertain whether final height in tall boys will really be reduced by treatment with BRC. BRC was kindly provided by Dr. R. Schmidt, Sandoz Ltd.
